Literature DB >> 20043026

Pazopanib.

Ronald M Bukowski, Uma Yasothan, Peter Kirkpatrick.   

Abstract

In October 2009, pazopanib (Votrient; GlaxoSmithKline)--a multikinase inhibitor with targets that include vascular endothelial growth factor receptors--was approved by the US FDA for the treatment of advanced renal cell carcinoma.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20043026     DOI： 10.1038/nrd3073

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  8 in total

1.  Sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Everolimus.

Authors:  Michael B Atkins; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 4.  Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

Authors:  Daniel Y C Heng; Ronald M Bukowski
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

5.  Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.

Authors:  Philip A Harris; Amogh Boloor; Mui Cheung; Rakesh Kumar; Renae M Crosby; Ronda G Davis-Ward; Andrea H Epperly; Kevin W Hinkle; Robert N Hunter; Jennifer H Johnson; Victoria B Knick; Christopher P Laudeman; Deirdre K Luttrell; Robert A Mook; Robert T Nolte; Sharon K Rudolph; Jerzy R Szewczyk; Anne T Truesdale; James M Veal; Liping Wang; Jeffrey A Stafford
Journal:  J Med Chem       Date:  2008-07-12       Impact factor: 7.446

Review 6.  Recent progress in the management of advanced renal cell carcinoma.

Authors:  Jorge A Garcia; Brian I Rini
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

7.  Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Authors:  Rakesh Kumar; Victoria B Knick; Sharon K Rudolph; Jennifer H Johnson; Renae M Crosby; Ming-Chih Crouthamel; Teresa M Hopper; Charles G Miller; Laura E Harrington; James A Onori; Robert J Mullin; Tona M Gilmer; Anne T Truesdale; Andrea H Epperly; Amogh Boloor; Jeffrey A Stafford; Deirdre K Luttrell; Mui Cheung
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

8.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321
  8 in total
  35 in total

1.  Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization.

Authors:  Jeremy M Sivak; Allison C Ostriker; Amber Woolfenden; John Demirs; Rosemarie Cepeda; Debby Long; Karen Anderson; Bruce Jaffee
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

2.  Gene and drug matrix for personalized cancer therapy.

Authors:  Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

3.  A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.

Authors:  Kristine K Deibler; Rama K Mishra; Matthew R Clutter; Aleksandar Antanasijevic; Raymond Bergan; Michael Caffrey; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

Review 4.  Concise drug review: pazopanib and axitinib.

Authors:  Robin M J M van Geel; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2012-06-25

5.  Quantitative implementation of the endogenous molecular-cellular network hypothesis in hepatocellular carcinoma.

Authors:  Gaowei Wang; Xiaomei Zhu; Jianren Gu; Ping Ao
Journal:  Interface Focus       Date:  2014-06-06       Impact factor: 3.906

Review 6.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

Review 7.  Novel strategies for treating relapsed/refractory urothelial carcinoma.

Authors:  Gopa Iyer; Matthew I Milowsky; Dean F Bajorin
Journal:  Expert Rev Anticancer Ther       Date:  2010-12       Impact factor: 4.512

8.  Synthesis and biological evaluation of novel 5-chloro-N-(4-sulfamoylbenzyl) salicylamide derivatives as tubulin polymerization inhibitors.

Authors:  Alaaeldin M F Galal; Maha M Soltan; Esam R Ahmed; Atef G Hanna
Journal:  Medchemcomm       Date:  2018-07-26       Impact factor: 3.597

9.  DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.

Authors:  Meng-yuan Li; Yong-cong Lv; Lin-jiang Tong; Ting Peng; Rong Qu; Tao Zhang; Yi-ming Sun; Yi Chen; Li-xin Wei; Mei-yu Geng; Wen-hu Duan; Hua Xie; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

Review 10.  Targeting of proangiogenic signalling pathways in chronic inflammation.

Authors:  Sander W Tas; Chrissta X Maracle; Emese Balogh; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2015-12-03       Impact factor: 20.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.